The effect of repeat oral supratherapeutic dosing of the BRAF inhibitor dabrafenib on QTc interval was assessed in patients with BRAF V600-mutant tumours.
Introduction
The mitogen-activated protein kinase pathway, consisting of transduction cascade signalling proteins RAS, RAF, MEK and ERK, is known to play a key role in the proliferation of many human cancers [1] [2] [3] . Dabrafenib is a BRAF inhibitor approved at a dose of 150 mg twice daily (BID) for treating unresectable or metastatic BRAF V600E/K-mutant melanoma with or without trametinib [4, 5] . In this patient population, treatment with combination dabrafenib and trametinib has been shown in pivotal phase 2 and phase 3 trials to result in significantly longer progression-free survival and improved overall survival compared with BRAF inhibitor monotherapy [6] [7] [8] . Additionally, with extended follow-up, long-term clinical benefit and tolerability have been demonstrated with the combination in some patients [9] [10] [11] .
Dabrafenib is metabolized through CYP2C8-and CYP3A4-mediated oxidation to form hydroxy-dabrafenib, which is further oxidized by CYP3A4 to carboxy-dabrafenib. Carboxy-dabrafenib can be decarboxylated via a nonenzymatic process to form desmethyl-dabrafenib, which is also metabolized by CYP3A4 [4, 12] . Hydroxy-dabrafenib pharmacokinetics (PK) parallels that of the parent, dabrafenib, with a similar half-life (10 h), while the carboxy and desmethyl metabolites have been shown to exhibit longer half-lives (21-22 h ) and accumulate after repeat dosing [4] . Based on systemic exposure, relative potency and PK properties, both hydroxy-and desmethyl-dabrafenib are likely to contribute to the clinical activity of dabrafenib [4] . Following single-dose administration of dabrafenib, exposure increased in a dose-proportional manner. The increase in exposure was less than dose proportional after repeat BID dosing, likely due to induction of its own metabolism, and the mean accumulation ratio was 0.73.
Proarrhythmic effects of therapeutic agents have led to marketing withdrawals of non-antiarrhythmic drugs (e.g., terfenadine, cisapride), resulting in increased expectations from regulatory agencies for sponsors to assess potential cardiovascular effects of drugs in development prior to regulatory approval [13] . Although cardiotoxicity is not commonly observed with BRAF inhibitors (e.g., vemurafenib, sorafenib), clinical studies have correlated this class of agents with QT prolongation [14, 15] . Based on preclinical cardiac safety evaluations of the potential cardiovascular effect with dabrafenib (i.e., hERG repolarization inhibition assay, cardiac effect studies in dogs and rats), the risk of QT prolongation was assessed to be low in humans [16, 17] ; however, further clinical investigation was needed.
The study reported here evaluated the effect of repeated oral supratherapeutic dosing of dabrafenib 300 mg BID on QTc interval in patients with BRAF V600-mutant tumours. The potential relationship between plasma concentrations of dabrafenib and its metabolites (i.e., hydroxy-dabrafenib, carboxy-dabrafenib, desmethyl-dabrafenib) and QT interval was also assessed.
Methods

Patients
Male and female patients were eligible for study enrolment if they were ≥18 years of age with a BRAF V600 mutationpositive tumour, an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate baseline organ function and ability to swallow and retain oral medication. Additionally, patients enrolled in part 2 of the study had serum potassium, magnesium and total calcium levels within normal limits. Key exclusion criteria included history or evidence of specific cardiovascular conditions in the past 6 months, prespecified electrocardiogram (ECG) and cardiac conduction abnormalities, uncontrolled hypertension, personal or family history of long QT syndrome, any clinically significant gastrointestinal abnormalities that may affect absorption of orally administered medication and brain metastases (unless asymptomatic and ≤1 cm in the longest dimension or treated and stabilized 1 month after local therapy). Anticancer therapy ≤21 days prior to enrolment, chemotherapy regimens without delayed toxicity ≤14 days prior to enrolment, or use of investigational anticancer drugs ≤28 days preceding the first dose of study treatment were not permitted.
The study was conducted in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and Good Clinical Practice and applicable patient privacy requirements, and the ethical principles outlined in the 2008 Declaration of Helsinki. The protocol and informed consent were approved by all local institutional review boards. Written informed consent was obtained from each patient prior to initiation of any study-specific procedures.
Study design and treatment
This was a phase 1, multicentre, two-part study in patients with BRAF V600-mutant tumours (GlaxoSmithKline study BRF113773; ClinicalTrials.gov, NCT01738451; Figure 1 ). In part 1, the primary objective was to evaluate the safety and tolerability of dabrafenib 225 or 300 mg BID to inform the part 2 dose. In part 1, cohort 1 (225 mg BID), if ≤1 dose limiting toxicity (DLT) occurred during the 14-day window, enrolment was to proceed to the next cohort at the higher dose (300 mg BID). If ≥2 DLTs were observed, then cohort 2 was not to be initiated and a dabrafenib dose of 150 mg BID would have been administered in part 2. Upon completion of part 1, the dabrafenib 300-mg BID dose was selected for part 2.
The primary objective of part 2, a single-blinded study, was to evaluate the effect of supratherapeutic dabrafenib 300 mg BID on the duration of baseline-adjusted, placebocorrected, time-matched QT interval corrected for heart rate by the Fridericia formula (QTcF) in patients with BRAF V600 mutation-positive tumours. Secondary objectives were to evaluate the effect of dabrafenib on ECG parameters, characterize the relationship between plasma concentrations of dabrafenib and its metabolites (i.e., hydroxy-dabrafenib, carboxy-dabrafenib, desmethyl-dabrafenib) and changes in QTc intervals, characterize the PK of dabrafenib and its metabolites on study days 1 and 8, and assess the short-term safety of repeated oral doses of dabrafenib 300 mg BID.
Patients received a dabrafenib-matched placebo on study day À1, a dabrafenib 300-mg single dose on study day 1, dabrafenib 300 mg BID on study days 2-7, and dabrafenib 300 mg the morning of study day 8. Each day À1, day 1 and day 8 dose was followed by 24-h 12-lead Holter ECG monitoring and PK serial blood sample collection. The effect of dabrafenib on the QTc interval was determined by timematched ECGs obtained in triplicate at the same time points relative to dosing on days 1 and 8. If a dose reduction was required before ECG evaluation, patients were considered evaluable unless the dose was reduced to <150 mg BID. Study procedure times were held consistent across the three ECG/PK study days to minimize circadian effects on ECGs (e.g., patients fasted overnight, with food/drink allowed after Figure 1 Study design for (A) part 1 and (B) part 2. In part 2, patients received 300 mg dabrafenib-matched placebo on day À1 followed by a single dose of dabrafenib 300 mg on day 1, then dabrafenib 300 mg BID on days 2 to 7. On day 8, all patients received a single dose of dabrafenib 300 mg. Key study assessments are noted for screening and days À1, 1 and 8. BID, twice daily; ECG, electrocardiogram; PK, pharmacokinetics; QTc, corrected QT interval.
a A single dose of study treatment was taken in the morning of day 8. b A single dose of study treatment was taken in the morning of days À1, 1 and 8 the 4-h [lunch] and 10-h [dinner] postdose ECG/PK samples), and other than assessment of vital signs and safety ECGs, no study procedures were performed during this period. In parts 1 and 2, coadministration of strong/moderate/ mild inducers or inhibitors of CYP3A4, CYP2C8, P-gp and BCRP were prohibited during the study. In part 2, coadministration of medications that were known to prolong the QT interval and have a risk of causing Torsades de pointes were also prohibited.
Patients who were eligible for continued dabrafenib treatment based on ongoing clinical benefit may have continued in the rollover study BRF114144 (ClinicalTrials.gov, NCT01231594). Standard 12-lead safety ECGs were performed for realtime assessment and were not included in the primary QT analysis, which used only data from the continuous 24-h Holter ECG recordings. The postdose safety ECG collection time point was timed to coincide with the maximum plasma concentration (C max ) of dabrafenib (median time to C max [T max ], 2 h). Echocardiograms evaluating left ventricular ejection fraction (LVEF) and both right-and left-sided valvular lesions were performed at baseline to assess cardiac ejection fraction and cardiac valve morphology to determine study eligibility, and again on day 8.
Safety and disease assessments
Ambulatory BP readings, extracted from continuous 24-h ambulatory BP monitor recordings, were determined at the same time points relative to dosing on days 1 and 8.
Because some patients may have also enrolled in the rollover study (BRF114144) if eligible after completing participation in the current study, disease assessment was performed at screening and included imaging (e.g., computed tomography, magnetic resonance imaging, bone scan, plain radiograph) and physical examination (as indicated for palpable/superficial lesions) or blood samples for tumour marker analysis. Due to the short study duration, no additional disease assessments were collected after screening.
Pharmacokinetic analyses
In part 1, serial blood samples for PK analysis were obtained at the same time points relative to dosing on days 1 and 8 (predose and 1, 1.5, 2, 3, 4, 6, 8 and 10 h postdose). In part 2, serial blood PK samples were obtained at the same time points relative to dosing on study days À1, 1 and 8 (predose; 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 h postdose). Samples obtained on days 1 and 8 were assayed for dabrafenib and metabolite (hydroxy-dabrafenib, carboxy-dabrafenib and desmethyldabrafenib) plasma concentrations.
Dabrafenib and metabolite assay
Plasma samples were analysed for dabrafenib, hydroxydabrafenib and desmethyl-dabrafenib using validated liquid-liquid extraction methods, and for carboxydabrafenib using protein precipitation followed by ultra-high-performance liquid chromatography tandem mass spectrometry. The lower limit of quantification (LLOQ) for dabrafenib, hydroxy-dabrafenib and desmethyl-dabrafenib was 1 ng ml À1 for a 50-μL aliquot of human plasma, with a higher limit of quantification (HLOQ) of 1000 ng ml À1 . The LLOQ for carboxy-dabrafenib was 5 ng ml À1 for a 25-μl aliquot of human plasma, with an HLOQ of 5000 ng ml À1 .
Further details for this assay were reported previously [12] . Quality control (QC) samples prepared at three different concentration levels were analysed with each batch of sample, with no more than one-third of the total QC results and no more than one-half of the results from each concentration level deviating from the nominal concentration by more than 15%. Precision (% coefficient of variation; CV) between runs were ≤6.6%, ≤6.4%, ≤7.3% and ≤7.0%, for dabrafenib, hydroxy-dabrafenib, desmethyl-dabrafenib and carboxydabrafenib, respectively. Stability of the samples under different conditions was assessed and supported the handling and storage conditions of the study.
Pharmacodynamic analyses
Continuous digital Holter-extracted ECG interval and morphology data were acquired and stored electronically. Triplicate ECGs were extracted at approximately 2-min intervals for each protocol-defined time point from 24-h highresolution Holter recordings and submitted to the validated central ECG core laboratory for analysis. ECGs were analysed by ERT (Philadelphia, USA) using the EXPERT analysis process based on Standard Lead II as the primary lead with V5 or another lead as an alternative option if the T-waves were not well defined, with manual overread, and structured quality control. A limited number of central ECG overreaders were used, and all ECGs for a given patient were overread by the same reader.
Baseline QT/QTc values were determined on study day À1 using time-matched ECGs obtained from the Holter monitor at approximately the same time points planned for study days 1 and 8. The mean from triplicate ECGs was evaluated at each time point.
Statistical analyses
This study was designed to estimate the effect of repeat oral doses of dabrafenib on the QTcF interval vs. placebo. No formal hypothesis was tested. Point estimates and corresponding 90% CI were constructed for the baseline-adjusted difference between the mean QTcF interval with dabrafenib and with placebo at each time point.
The QTcF change from baseline on study days 1 and 8 was analysed separately by a repeated-measures analysis of variance, fitting patients as random effects and treatment group, time point and treatment group × time point interactions as fixed effects. Baseline QTcF intervals for each treatment and sex were included as covariates. The mean differences in changes from baseline between treatment and corresponding 90% CIs were provided for each time point. Analyses
The effect of dabrafenib and metabolites on cardiac repolarization described for QTcF interval were also carried out for other QT interval correction methods (i.e., Bazett-corrected QT interval [QTcB] and individually corrected QT interval [QTcI] ). The QTcI was calculated as follows:
The part 1 analysis population included the all-treated population for safety analysis (all patients who received ≥1 dose of study treatment), where patients were considered evaluable if they received study treatment on study days 1-8 and completed the study day 15 visit. The part 2 analysis populations included the all-treated/safety analysis population, the PK population (all patients in the all-treated population from whom a PK sample was obtained and analysed), and the pharmacodynamics (PD) population (all patients from the all-treated population who completed the ECG acquisition via Holter monitoring at ≥1 time point on study days À1, 1 and 8). Evaluable patients in part 2 met the following criteria: (1) dosing adherence (no dabrafenib dose reduction to <150 mg BID due to safety or tolerability issues and received all planned doses of study treatment on study days À1 and 1; OR received all planned doses of study treatment on study day À1, missed ≤2 nonconsecutive doses of study treatment during study days 1-5, missed ≤1 planned dose of study treatment on study days 6 or 7, and received the planned dose of study treatment on study day 8); (2) ECG acquisitions (completed ECG acquisitions via Holter monitoring through the 24-h time period and missed ≤3 consecutive time points on study days À1 and 1 or À1 and 8); and (3) baseline ECG acquisitions (≥ 1 of 3 replicate ECG readings from all baseline time points [À30, À15 and 0 min] on study days À1 and 1 and ≥ 2 of 3 replicates from ≥2 baseline time points on study days À1 and 1).
Dabrafenib and metabolite PK parameters were calculated by standard noncompartmental analysis using WinNonlin version 6.3 (Pharsight Corporation, St. Louis, MO). The actual time of blood sample collection was used to calculate the PK parameters. Mixed-effects modelling was performed using NONMEM version 7.3 (ICON, Dublin, Ireland). The modelling effort was a descriptive exploratory analysis in which inferences were based on parameter estimates, their estimation precision and diagnostic plots. First, the appropriateness of QTcF and QTcB correction for the R-R interval was assessed by determining the slope of the relationship between QTc and R-R. As neither the Fridericia nor the Bazett correction method was found to adequately correct for R-R, the relationship between dabrafenib/metabolite concentrations and QT was modelled directly and a more appropriate correction factor estimated, along with incorporating a cosine function to describe the circadian rhythm in the corrected QT data. One-, two-and three-cosine functions were investigated. The model was built in a step-wise process, first estimating the correction factor, and secondly, including a cosine function to describe the circadian rhythm in the QTc interval. The estimates of the correction factor and cosine function parameters were compared for QT data prior to administration of dabrafenib and all data (prior and post dabrafenib administration). Next, the effects of dabrafenib and each metabolite on QT were assessed both individually and simultaneously in 1 model using linear terms.
The model is presented as follows:
where QT ij is the QT interval for individual i and time j, BQT is the baseline QT interval after correction, A 1i , A 2i and A 3i are the individual amplitudes, ϕ 1i , ϕ 2i and ϕ 3i are the acrophase parameters, Slope is the linear drug effect, C ij is drug concentration for subject i at time j, and ε is the additive residual error. Interindividual random effects were initially included on all structural parameters. Distributions of interindividual random effects were described by an exponential error model for the correction factor and cosine function parameters and an additive error model for baseline QTc estimate and linear effect terms. Covariates of sex, age, weight and race were investigated. Covariates were first added univariately if a relationship was suspected in the individual random effects against covariates plots. All significant covariate-parameter relationships (> 6.83-point decrease in objection function value [OFV]) were then entered in the model simultaneously. A step-wise deletion procedure was then implemented. For continuous covariates, a power function was utilized. For categorical covariates, the fractional change in the typical parameter value was determined.
Structural model selection was driven by the data and was based on goodness-of-fit plots, successful convergence, plausibility and precision of parameter estimates and OFV.
Simulations using the final model were performed to predict the maximum baseline-adjusted, placebo-corrected, time-matched QTc (ΔΔQTc) interval at the maximum concentrations observed. All modelling was performed using first-order conditional estimation with interaction.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [18] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [19] .
Results
Patient characteristics
Twelve patients in part 1 and 32 patients in part 2 with BRAF V600-mutant tumours were enrolled and included in the alltreatment population (Table 1; Table S1 ). All 12 patients (100%) completed part 1. In part 2, two patients were excluded from the evaluable population for PD assessment: one patient was withdrawn from the study on the physician's advice due to a prolonged partial response after placebo treatment, and one patient had a serious AE (SAE) of atrial fibrillation and was not evaluable because of five consecutive poor Holter ECG tracings following placebo treatment.
Patients in part 2, aged between 28 and 81 years, were mostly white and male (Table 1) . Melanoma and colon/rectal cancer were the most common primary tumour types, and >90% of patients had stage IV disease at screening. Prior anticancer therapies included surgery (91%), chemotherapy (53%), biologic therapy (38%), small-molecule targeted therapy (25%), immunotherapy (13%), radioactive therapy (13%) and hormone therapy (6%).
Pharmacokinetics
Based on the safety and tolerability data in part 1 (dabrafenib PK data in Table S6 ), the dose of 300 mg BID was selected for part 2 (QTc evaluation), where patients received a single dose of dabrafenib 300 mg on study day 1, dabrafenib 300 mg BID on study days 2-7, and a single dose of dabrafenib 300 mg on day 8. Twenty-nine patients of the 31 evaluable for PK analysis administered all doses as planned. One patient missed one dose (300 mg) before day 8 and one had an extra dose (300 mg) after the PK day. Geometric mean dabrafenib area under the concentration-time curve from 0 to 12 h (AUC (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) ) and C max values following the repeat dose 300 mg BID on day 8 were 12 636 ng h ml À1 and 3752 ng ml À1 , respectively ( Table 2) . Dabrafenib AUC (0-12) was lower on day 8 than on day 1. Similarly, the AUC (0-12) with hydroxydabrafenib was lower on day 8 than on day 1. Median T max on day 1 with dabrafenib and hydroxy-dabrafenib was 1.5 and 4 h, respectively. With the carboxy-dabrafenib and desmethyl-dabrafenib metabolites, exposure was higher on day 8, and median T max was 4 h with both metabolites. On the respective day when exposure was highest with dabrafenib and each metabolite, T max with each molecule was observed within the time window during which ECG measurements were collected.
Impact of dabrafenib on QT
Thirty patients were evaluable for change in QTcF interval from baseline at each time point with dabrafenib vs. timematched placebo. To demonstrate a lack of effect, the upper 90% CI limit (95th percentile) for the treatment difference (dabrafenib minus placebo) at each time point needed to be completely contained within 10 msec. No effect on QT interval on days 1 or 8 was observed compared with time-matched placebo ( Figure 2A ; Table S2 ). The highest observed mean difference between active treatment and placebo was 2.86 msec, with an upper 90% CI of 7.15 msec at 10 h postdose on study day 8.
To assess the appropriateness of various correction factors (QTcF, QTcB and QTcI), slopes of the relationship between each correction factor and R-R were determined. Based on the 95% CI, the slope of the relationship between QTcF and R-R was significantly different from zero. A relationship was also found between QTcB and R-R. The 95% CI for the relationship between QTcI and R-R included zero; thus, QTcI was considered an appropriate correction factor. As such, although QTcF was defined as the primary QT endpoint in this study, and is widely accepted as the optimal QT corrector, this analysis was also performed using QTcI and indicated a lack of effect of dabrafenib on QT interval prolongation ( Figure 2B , Table S3 ).
Categorical analysis of QTc
No patients had a maximum change from baseline of >60 msec or a maximum post-baseline value >500 msec for QTcF. One patient (3%) had increases in QTcF >30 to ≤60 msec, and two patients (7%) had increases in QTcI of the same magnitude following treatment with dabrafenib. For QTcB, ten patients (33%) had increases of >30 to ≤60 msec.
Overall, no dabrafenib-or placebo-arm patients showed QTcF, QTcI or QTcB values of >480 or >500 msec. Two patients (7%) had QTcF values >450 to ≤480 msec after placebo and dabrafenib treatment; seven patients (23%) and eight patients (27%) had QTcI values >450 to ≤480 msec after placebo and dabrafenib treatment, respectively; and ten patients (33%) and eighteen patients (60%) had QTcB values >450 to ≤480 msec after placebo and dabrafenib treatment, respectively.
Effect on heart rate
Plots of the mean by time point placebo-corrected change from baseline in heart rate are presented in Figure S4 , and heart rate change values compared with placebo are presented in Table S7 .
An exposure-related increase in heart rate was observed. On day 1, the placebo-corrected peak heart-rate effect of 10.2 bpm (90% CI, 6.41-14.00 bpm) at 10 h was synchronized with the time of maximum QT effect. During chronic 
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a Race was not recorded for one patient; however, his ethnicity was listed as Hispanic or Latino.
The effect of dabrafenib and metabolites on cardiac repolarization treatment, the maximum change in heart rate of 9.3 bpm (90% CI, 5.55-13.06 bpm) occurred at 6 h postdose. A residual effect on heart rate of 3.18 bpm (90% CI, 0.27-6.09 bpm) was present during chronic treatment (predose on day 8).
Relationship between PK and PD parameters
As neither the Fridericia nor the Bazett correction method adequately corrected for R-R ( Figure S1 ), the relationship between dabrafenib/metabolite concentrations and QT was modelled directly and a more appropriate correction factor estimated. A time course of the mean baseline-adjusted, placebo time-matched, individually corrected QT (ΔΔQTcPi) and concentrations of dabrafenib and each metabolite on days 1 and 8 showed an initial decrease in QTcPi that appeared to coincide with the time of maximum dabrafenib and hydroxy-dabrafenib concentrations, followed by an increase in QTcPi with the time of maximum concentration of carboxy-dabrafenib and desmethyl-dabrafenib on day 1 and slightly after on day 8 ( Figure 3) . A two-cosine function best described the circadian rhythm in the corrected QT data. The correction factor and cosine function parameter estimates were comparable when estimated with QT data prior to administration of dabrafenib and with all data (prior and post dabrafenib administration).
The effects of dabrafenib and each metabolite when assessed individually showed that both dabrafenib and hydroxydabrafenib were associated with lower QTc, and both desmethyl-dabrafenib and carboxy-dabrafenib were associated with higher QTc. To further explore the relationship, the effects of dabrafenib, desmethyl-dabrafenib, hydroxydabrafenib and carboxy-dabrafenib on the QTc interval were estimated simultaneously. In this model, only the effects of dabrafenib and desmethyl-dabrafenib were significant and included in the model. Sex, age, weight and race were found not to be predictors of the QTc interval or dabrafenib and its metabolites exposure-QTc relationships.
The final exposure QTc model included individualized correction and two-cosine functions to describe the circadian rhythm in the QTc interval. Dabrafenib and desmethyldabrafenib were found to affect the QTc interval, where higher dabrafenib concentrations were associated with lower QTc and higher desmethyl-dabrafenib concentrations were associated with higher QTc (Table S4 ). The goodness-of-fit diagnostic plots ( Figure S2 ) indicated the observed data were well described by the model. Bootstrap estimates were almost identical to the final model. Evaluation of the final model by visual predictive check indicated that it adequately described the observed data ( Figure S3 ). 
Simulation of PK/PD model
To characterize the impact of dabrafenib and desmethyldabrafenib concentrations on the QTc interval, QT was simulated for baseline records on days À1 and 1 (hour 0) and at the nominal time of the observed maximum desmethyldabrafenib concentration on days À1 and 1. The maximum desmethyl-dabrafenib concentration and associated dabrafenib concentration were used in the simulation along with associated R-R and clock times. The maximum baseline-adjusted, placebo-corrected, time-matched QTcF (ΔΔQTc) was calculated for each patient in 500 simulated trials, which showed that the predicted median ΔΔQTc at the maximum observed desmethyl-dabrafenib and associated dabrafenib concentration after administration of 300 mg BID was 3.32 msec (90% CI, À2.10-8.91 msec).
Safety and tolerability
In part 1, headache (n = 6 [50%]), nausea (n = 6 [50%]), arthralgia (n = 3 [25%]), hyperkeratosis (n = 3 [25%]), pyrexia (n = 3 [25%]), skin lesions (n = 3 [25%]) and vomiting (n = 3 [25%]) were among the more common AEs reported in three or more patients across the two dose cohorts (Table S5) (Table 3) . Four patients experienced at least one grade 3 AE, including hypophosphataemia (n = 3), arthralgia (n = 1), hypotension (n = 1; reported as an SAE) and neutropenia (n = 1). All remaining AEs in part 1 and part 2 were grade ≤2.
There were no fatal SAEs, and no AEs led to dose reduction, discontinuation of the study treatment, or withdrawal from the study in part 1 or part 2. SAEs with dabrafenib reported in part 2 included atrial fibrillation (n = 1) and hypotension (n = 1), both of which resolved and were not considered by the investigator to be related to study treatment.
No treatment-related abnormal LVEF results were observed post-baseline. Of the abnormal ECG results observed following treatment with dabrafenib, a majority were not considered clinically significant. The AE profile was consistent with that known for dabrafenib. 
Discussion
This study evaluated the risk of dabrafenib inducing QT prolongation at supratherapeutic exposures in patients with BRAF V600-mutant tumours. At the time this study was planned, it was considered inappropriate to perform a thorough QT study in healthy volunteers as outlined in the ICH E14 guidance [20] . Dabrafenib is both a substrate and an inducer of CYP3A4 and has nonlinear pharmacokinetics in humans after repeat BID dosing, likely due to induction of its own metabolism. Moreover, as some metabolites of dabrafenib are active and exposure to some of these increases over time, a multiple-dose study in healthy volunteers was ruled out. The ICH E14 guidance states that the duration of dosing in a QT study should be sufficient to characterize the effects of the drug and its active metabolites at relevant concentrations. Given the long half-life of the metabolites, the study was designed as a parallel group after repeat dosing to maximize exposure and avoid delaying active treatment in patients with BRAF-mutant tumours.
Given difficulties in designing and conducting a QTc study in patients with advanced cancer and the short duration that potentially active treatment can be delayed for patients with rapidly progressing disease, a positive control arm (e.g., moxifloxacin) was not included. In addition, the study duration was limited to 8 days to allow for measurement of QTc changes at maximum or near-maximum exposures of metabolites. Other key directives from the ICH guidance were incorporated, including the use of a supratherapeutic dose, time-matched ECGs at baseline, triplicate ECGs to reduce variability, a placebo control and PK collection at the time of ECG assessment (for determining potential concentration-response relationships). The safety profile of dabrafenib demonstrated in part 1 allowed the use of a supratherapeutic dose in patients with cancer. In addition, as dabrafenib is a substrate of CYP3A4 and CYP2C8, coadministration of strong inhibitors of these two enzymes Table 3 Summary of adverse events reported in ≥5% of patients in part 2 (alltreated population) has shown to increase the exposure to dabrafenib and some of its active metabolites [4, 21] ; therefore, the possibility of QT prolongation needed to be assessed at higher dabrafenib exposures. Moreover, although not considered clinically relevant, a 23% increase in AUC of dabrafenib and a 33% increase in AUC of desmethyl-dabrafenib is observed when dabrafenib is combined with trametinib [4] . The study results indicate the absence of a relevant effect of dabrafenib 300 mg on the QT interval compared with placebo on study days 1 or 8 based on repeated-measures statistical analysis of the change from baseline in QTcF. The absence of a relevant change in cardiac repolarization was further supported by the QTcI correction formula, which performed better than QTcF as a correction factor for changes in heart rate. There was a treatment effect of dabrafenib on mean heart rate on study days 1 and 8.
The administration of dabrafenib 300 mg on study day 1 in part 2 achieved C max levels (3704 ng ml À1 ) that were approximately 2.2 times higher than those previously reported for a single dabrafenib 150-mg dose (phase 1/2 study BRF113220, part D; 1669 ng ml À1 ) [22] . Similarly, geometric mean AUC from 0 to infinity (AUC (0-∞) ) after administration of 300 mg on day 1 in part 2 was 2.5-fold greater than the AUC (0-∞) values previously observed for a single dabrafenib 150-mg dose (BRF113220, part D; 7291 ng h ml À1 ). These results are consistent with dose-proportional increases in dabrafenib exposure after single doses of ≤300 mg. Plasma dabrafenib concentrations likely were not at steady state by day 8. However, geometric mean AUC from zero to the time of the last quantifiable concentration (AUC (0-τ) ) on day 8 in part 2 was approximately 2.7-to 3-fold greater than the geometric mean AUC (0-τ) values previously observed after administration of dabrafenib 150 mg BID for ≥21 days (phase 3 study BREAK-3/BRF113683; BRF113220) [22, 23] . Although the primary assessment was to be performed on the ΔΔQTc, adequacy analysis indicated that neither the Bazett nor the Fridericia correction method adequately corrected for R-R changes. Therefore, the effect of the concentration of dabrafenib and its metabolites on QTc interval was determined directly using the population-derived QT correction, QTcPi, which included interpatient variability. The exposure QTc model included an individualized correction and two-cosine functions to describe the circadian rhythm in the QTc interval. Dabrafenib and desmethyl-dabrafenib were found to affect the QTc interval: higher dabrafenib concentrations were associated with lower QTc, and higher desmethyl-dabrafenib concentrations were associated with higher QTc.
A possible delay in the effect (hysteresis) was evident from the mean ΔΔQTcPi and mean dabrafenib, hydroxydabrafenib, carboxy-dabrafenib and desmethyl-dabrafenib concentration vs. nominal time. However, as the final model adequately described the data without a delay in effect, it can be concluded that the apparent hysteresis was due to the interaction of the two different relationships, with higher dabrafenib concentrations decreasing QTc initially and higher desmethyl-dabrafenib concentrations subsequently increasing QTc. The final mixed-effects model predicted a median ΔΔQTc at the maximum observed desmethyldabrafenib and associated dabrafenib concentration of 3.32 msec (90% CI, À2.10-8.91 msec). The median increase in QTc was <5 msec, and the upper limit of the 90% CI was <10 msec after administration of the supratherapeutic dose of dabrafenib 300 mg BID.
The majority of the AEs reported were consistent with the known AE profile of dabrafenib [4, 24] , with no new safety signals observed.
The selected schedule of dabrafenib 300 mg BID administration over 8 days achieved supratherapeutic concentrations. Compared with placebo, there was no relevant effect of dabrafenib on QTcF or QTcI prolongation, based on ECG measurements collected at times representing the maximal plasma concentrations of dabrafenib and its metabolites at a supratherapeutic dose.
Dabrafenib is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600 K mutations as detected by an US Food and Drug Administration (FDA)-approved test. The heart rate-corrected QT prolongation potential of trametinib was also assessed in a separate dedicated QT study, and no clinically relevant QTc prolongation was detected [5] . Overall, these results confirm that the potential risk of dabrafenib treatment effect on QTc prolongation in patients with BRAF-mutant tumours is low when dabrafenib is administered as a single agent and in combination with trametinib.
The challenges of evaluating QTc effects in oncology have been widely discussed, and different approaches have been developed to detect the effects on the QT/QTc interval in cases where it was not possible to conduct a thorough QT study [25] . A recent publication described how the use of an integrated nonclinical and clinical assessment of a drug's effect on the QT interval and other cardiac parameters, including assessment of cardiac depolarization and repolarization in target patient populations, could potentially obviate the need for a standalone QT study [26] . The collection of ECGs at multiple time points under tightly controlled settings that target a broad range of doses in early phase 1/2 studies is essential during the development of a drug to ensure that sufficient information is available for the evaluation of the drug concentration-related effects on QTc prolongation. A similar approach was used for dabrafenib in the initial submission package in 2012, but the data were considered insufficient to rule out the possibility of QT prolongation. The exposure-response analysis was conducted with the data from the first-time-in-human (FTIH) study to determine the relationship between the independently manually read QTc interval and time-matched plasma concentrations of dabrafenib and each of its metabolites using a nonlinear mixed-effects model. It suggested that dabrafenib had no effect on QTcP (P was the estimated correction factor) and the median change in QTcP was predicted to be ≤5.5 msec for the metabolites after administration of dabrafenib 300 mg BID. The FTIH study was conducted with gelatin capsules and explored a broad range of doses; however, during the development of dabrafenib, the gelatin capsules used in earlyphase studies such as the FTIH were replaced with hydroxypropyl methylcellulose (HPMC) capsules, which provided better stability and enhanced shelf life. The relative bioavailability of dabrafenib in HPMC capsules was 1.80 compared with gelatin capsules following single oral doses [27] . As such, the data from the FTIH study, which evaluated doses of dabrafenib in gelatin capsules up to 300 mg BID, did not provide safety, tolerability and PK analysis for the potentially higher exposures that might occur following the administration of 300 mg BID in HPMC capsules. At the time of the initial submission in 2012, the QT study for dabrafenib was already designed and planned, and the FDA requested that the trial be completed as a post-marketing requirement. The current study demonstrated how a study design can be modified to successfully assess the QTc risk for an anticancer agent in patients in a situation where insufficient data prevents a robust concentration-QTc analysis, as previously described [26] .
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Additional Supporting Information may be found online in the supporting information tab for this article. Figure S3 Visual predictive check goodness-of-fit plots by day. A total of 500 simulations were performed with the final PK/PD parameters for (A) placebo on day −1, (B) dabrafenib 300 mg on day 1, and (C) dabrafenib 300 mg on day 8 to compare the distribution of simulated QT with that of the observed data. The majority of observed data fell within the range of the 5th and 95th percentiles of the simulated values (gray zones), indicating that the final model sufficiently described the observed QT data. obs, observed; PD, pharmacodynamics; PI, prediction interval; PK, pharmacokinetics; VPC, visual predictive check Figure S4 Mean (± SEM) change from each baseline in heart rate for (A) day 1 and (B) day 8. bpm, beats per minute; HR, heart rate; SEM, standard error of the mean The effect of dabrafenib and metabolites on cardiac repolarization
